Singapore Clinical Trial: A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation.

Singapore, Sept. 20 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asci... Read More

Singapore Clinical Trial: A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by asciminib plus blinatumomab in pediatric, adolescent, and young adult participants with relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

Singapore, Sept. 20 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib wit... Read More

Singapore Clinical Trial: A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease

Singapore, Sept. 20 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy... Read More

Singapore Clinical Trial: CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion

Singapore, Sept. 20 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitax... Read More

Singapore Clinical Trial: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Singapore, Sept. 20 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus A... Read More

Singapore Clinical Trial: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Singapore, Sept. 20 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus A... Read More

Singapore Clinical Trial: Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations

Singapore, Sept. 20 -- The Health Sciences Authority received information related to the study titled 'Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvan... Read More

The four enoughs of the Sundiata Post Model: From the desk to the world, By Max Amuchie

Nigeria, Sept. 20 -- There is something almost deceptively ordinary about a notebook. It is paper. A surface for writing. It may sit on a desk, in a drawer, beside a bed or, under less ordinary circu... Read More

Asian Games 2026: Indian women's table tennis team starts off with sensational come-from-back win

Aichi-Nagoya, Sept. 20 -- Indian women's table tennis started off their Asian Games 2026 campaign with a sensational come-from-behind win over Singapore in their Group F match on Sunday. India was tr... Read More

Mutual funds take Rs.2,495 crore exposure in NSE IPO anchor book: Nippon India Large Cap tops the list of 10 schemes

New Delhi, Sept. 20 -- Mutual fund schemes have been allotted shares worth nearly Rs.2,495 crore in the anchor portion of the NSE IPO, with 29 domestic mutual funds participating through 98 schemes. ... Read More

• ««
• «
• 3762
• 3763
• 3764
• 3765
• 3766
• 3767
• 3768
• 3769
• 3770
• 3771
• »
• »»